Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

National Institute of Allergy and Infectious Diseases (NIAID)

NIH Co-funds First New HIV Vaccine Efficacy Study in Seven Years

aids-hiv-vaccineBethesda, MD, November 29, 2016 — The National Institutes of Health (NIH) yesterday announced that the first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults.

The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus.

HVTN 702 aims to enroll 5,400 men and women, making it the largest and most advanced HIV vaccine clinical trial to take place in South Africa, where more than 1,000 people become infected with HIV every day. Continue reading

NIH Begins Testing Investigational Zika Vaccine in Humans

NIH in BlueBethesda, MD, August 3, 2016 ― The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced it has launched a clinical trial of a vaccine candidate intended to prevent Zika virus infection.  The early-stage study will evaluate the experimental vaccine’s safety and ability to generate an immune system response in participants.

At least 80 healthy volunteers ages 18-35 years at three study sites in the United States, including the NIH Clinical Center in Bethesda, Maryland, are expected to participate in the trial.

Scientists at NIAID’s Vaccine Research Center (VRC) developed the investigational vaccine — called the NIAID Zika virus investigational DNA vaccine — earlier this year. Continue reading